A Validated RP-HPLC Method for the Determination of Recombinant Human Insulin in Bulk and Pharmaceutical Dosage Form
A modified RP-HPLC method was developed for the quantitative determination of recombinant human insulin in bulk and pharmaceutical dosage form with reduced retention time. Study of the effects of the column temperature, pH of the mobile phase and presence of vial additives (phenol and m-cresol), or...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | E-Journal of Chemistry |
| Online Access: | http://dx.doi.org/10.1155/2010/147824 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559433361653760 |
|---|---|
| author | B. A. Moussa F. Farouk H. M. E. Azzazy |
| author_facet | B. A. Moussa F. Farouk H. M. E. Azzazy |
| author_sort | B. A. Moussa |
| collection | DOAJ |
| description | A modified RP-HPLC method was developed for the quantitative determination of recombinant human insulin in bulk and pharmaceutical dosage form with reduced retention time. Study of the effects of the column temperature, pH of the mobile phase and presence of vial additives (phenol and m-cresol), or impurities (A-21 Disamido) on the accuracy of the assay were assessed. Separation was achieved using a Hypersil BDS C-18 column and the mobile phase was composed of solution A (aqueous solution of 28.3 anhydrous Na2SO4g/L, pH 2.3) and solution B (28.5 g anhydrous Na2SO4 g/L in 50:50 mixture of water and acetonitrile, pH 2.3) in a ratio 48:52 (v/v) at 45–50 °C. The column temperature was 40 °C, the flow rate was 1 mL/min and detection was performed at 216 nm. The procedures were validated according to international conference on harmonization (ICH) guidelines. Recovery study was done applying standard addition technique for further validation of the procedure. The retention time of recombinant human insulin was 19.7 min as compared to 29 min obtained by the reference method. Analytical conditions fluctuations or presence of vial additives or impurities did not show any significant effect on the accuracy of the method. The prepared standard insulin solution in 0.01 N HCl was found to be stable for 5 days. Statistical comparison showed no significant difference between the described method and reference method regarding the accuracy and precision. The modified method can be applied for routine quality control applications for determination of recombinant human insulin. |
| format | Article |
| id | doaj-art-9ea8519b9b1b4b9fbe3b8b1299a9b587 |
| institution | Kabale University |
| issn | 0973-4945 2090-9810 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | E-Journal of Chemistry |
| spelling | doaj-art-9ea8519b9b1b4b9fbe3b8b1299a9b5872025-02-03T01:30:09ZengWileyE-Journal of Chemistry0973-49452090-98102010-01-017S1S449S45710.1155/2010/147824A Validated RP-HPLC Method for the Determination of Recombinant Human Insulin in Bulk and Pharmaceutical Dosage FormB. A. Moussa0F. Farouk1H. M. E. Azzazy2Department of Pharmaceutical Chemistry Faculty of Pharmacy, Cairo University, Cairo, EgyptEgyptian Company of Biological Products and Vaccines (VACSERA), Giza, EgyptDepartment of Chemistry, American University in Cairo, New Cairo, EgyptA modified RP-HPLC method was developed for the quantitative determination of recombinant human insulin in bulk and pharmaceutical dosage form with reduced retention time. Study of the effects of the column temperature, pH of the mobile phase and presence of vial additives (phenol and m-cresol), or impurities (A-21 Disamido) on the accuracy of the assay were assessed. Separation was achieved using a Hypersil BDS C-18 column and the mobile phase was composed of solution A (aqueous solution of 28.3 anhydrous Na2SO4g/L, pH 2.3) and solution B (28.5 g anhydrous Na2SO4 g/L in 50:50 mixture of water and acetonitrile, pH 2.3) in a ratio 48:52 (v/v) at 45–50 °C. The column temperature was 40 °C, the flow rate was 1 mL/min and detection was performed at 216 nm. The procedures were validated according to international conference on harmonization (ICH) guidelines. Recovery study was done applying standard addition technique for further validation of the procedure. The retention time of recombinant human insulin was 19.7 min as compared to 29 min obtained by the reference method. Analytical conditions fluctuations or presence of vial additives or impurities did not show any significant effect on the accuracy of the method. The prepared standard insulin solution in 0.01 N HCl was found to be stable for 5 days. Statistical comparison showed no significant difference between the described method and reference method regarding the accuracy and precision. The modified method can be applied for routine quality control applications for determination of recombinant human insulin.http://dx.doi.org/10.1155/2010/147824 |
| spellingShingle | B. A. Moussa F. Farouk H. M. E. Azzazy A Validated RP-HPLC Method for the Determination of Recombinant Human Insulin in Bulk and Pharmaceutical Dosage Form E-Journal of Chemistry |
| title | A Validated RP-HPLC Method for the Determination of Recombinant Human Insulin in Bulk and Pharmaceutical Dosage Form |
| title_full | A Validated RP-HPLC Method for the Determination of Recombinant Human Insulin in Bulk and Pharmaceutical Dosage Form |
| title_fullStr | A Validated RP-HPLC Method for the Determination of Recombinant Human Insulin in Bulk and Pharmaceutical Dosage Form |
| title_full_unstemmed | A Validated RP-HPLC Method for the Determination of Recombinant Human Insulin in Bulk and Pharmaceutical Dosage Form |
| title_short | A Validated RP-HPLC Method for the Determination of Recombinant Human Insulin in Bulk and Pharmaceutical Dosage Form |
| title_sort | validated rp hplc method for the determination of recombinant human insulin in bulk and pharmaceutical dosage form |
| url | http://dx.doi.org/10.1155/2010/147824 |
| work_keys_str_mv | AT bamoussa avalidatedrphplcmethodforthedeterminationofrecombinanthumaninsulininbulkandpharmaceuticaldosageform AT ffarouk avalidatedrphplcmethodforthedeterminationofrecombinanthumaninsulininbulkandpharmaceuticaldosageform AT hmeazzazy avalidatedrphplcmethodforthedeterminationofrecombinanthumaninsulininbulkandpharmaceuticaldosageform AT bamoussa validatedrphplcmethodforthedeterminationofrecombinanthumaninsulininbulkandpharmaceuticaldosageform AT ffarouk validatedrphplcmethodforthedeterminationofrecombinanthumaninsulininbulkandpharmaceuticaldosageform AT hmeazzazy validatedrphplcmethodforthedeterminationofrecombinanthumaninsulininbulkandpharmaceuticaldosageform |